Literature DB >> 9308122

Historical aspects of treatment of patients with cirrhosis and ascites.

B A Runyon1.   

Abstract

The most striking feature of the history of treatment of patients with cirrhosis and ascites is the recurring cycle of initial enthusiasm for a new modality based on uncontrolled observations, followed by reports of complications and failures and/or negative randomized control trials (RCTs). The RCTs tend to be performed rather late, after it is realized that there are problems with the new treatment. In 1975 Tom Chalmers made a plea for randomization of the first patient treated with a new modality. The appropriateness of performing RCTs very early in the evaluation of a new treatment cannot be overemphasized today. Carefully designed RCTs that focus on appropriate subsets of patients and evaluate clinically important endpoints (rather than easier-to-measure, but unimportant indirect endpoints) are the keys to "evidence-based medicine" that will lead to the best outcomes for our patients. If we do not remember that uncontrolled studies regularly lead us into years or even decades of "blind alleys" of investigation, we are destined to repeat the mistakes of the past.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9308122     DOI: 10.1055/s-2007-1007195

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  11 in total

1.  Is there still a need for albumin infusions to treat patients with liver disease?

Authors:  P Ginès; V Arroyo
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

2.  Effect of albumin-furosemide mixtures on response to furosemide in cirrhotic patients with ascites.

Authors:  D C Brater; N Chalasani; J C Gorski; J C Horlander; R Craven; H Hoen; J Maya
Journal:  Trans Am Clin Climatol Assoc       Date:  2001

Review 3.  Current management of portal hypertension.

Authors:  Andrew S Wright; Layton F Rikkers
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

4.  The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites.

Authors:  V L Misra; R Vuppalanchi; D Jones; M Hamman; P Y Kwo; C Kahi; N Chalasani
Journal:  Aliment Pharmacol Ther       Date:  2010-10       Impact factor: 8.171

5.  Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial.

Authors:  Roberto-Giulio Romanelli; Giorgio La Villa; Giuseppe Barletta; Francesco Vizzutti; Fabio Lanini; Umberto Arena; Vieri Boddi; Roberto Tarquini; Pietro Pantaleo; Paolo Gentilini; Giacomo Laffi
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

Review 6.  Evaluation and management of patients with refractory ascites.

Authors:  Bahaa Eldeen Senousy; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

Review 7.  Liver cirrhosis.

Authors:  Detlef Schuppan; Nezam H Afdhal
Journal:  Lancet       Date:  2008-03-08       Impact factor: 79.321

Review 8.  Albumin for end-stage liver disease.

Authors:  June Sung Lee
Journal:  Korean J Intern Med       Date:  2012-02-28       Impact factor: 2.884

9.  Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis.

Authors:  Takuya Iwamoto; Masaki Maeda; Takuro Hisanaga; Issei Saeki; Koichi Fujisawa; Toshihiko Matsumoto; Isao Hidaka; Tsuyoshi Ishikawa; Taro Takami; Isao Sakaida
Journal:  Intern Med       Date:  2016-10-15       Impact factor: 1.271

Review 10.  Pathogenesis and management of alcoholic liver cirrhosis: a review.

Authors:  Yi-Wen Huang; Sien-Sing Yang; Jia-Horng Kao
Journal:  Hepat Med       Date:  2011-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.